Key Takeaways
- Flat margins, one-time offsets: EBIT margin held at 14.45% QoQ only because a 300 bps earn-out reversal compensated for 200 bps of headwinds from transition costs, lower utilization, and elevated travel.
- Top customer decline is planned, not panic: The largest client fell $3.2 mn QoQ, the second straight quarter of decline, driven by contracted productivity improvements in a large deal, not re-negotiation or surprise.
- Healthcare vertical delivered the quarter: Healthcare & Life Sciences grew 15% QoQ, powered by a large win and years of team-building; management expects it to lead FY25 growth as well.
- Demand environment is steady, not accelerating: Management sees the same demand as 2-3 quarters ago, with no change yet; hi-tech faces enterprise software headwinds for the next few quarters.
- What to watch next quarter: Whether BFSI ramp-ups from new logos accelerate, whether the capacity built from lateral hires converts to margin leverage, and any M&A announcement in Healthcare or BFSI at the Data/AI cusp.
Margin Mechanics
- Headwinds stacked up: One-time transition costs on vendor consolidation deals hit margins by 110 bps, lateral offshore hires building capacity and planned onsite-to-offshore transitions lowered utilization from 81.5% to 80% (50 bps impact), and elevated travel for FY25 planning added 40 bps. Total operational drag: 200 bps.
- Earn-out reversal saved the quarter: A 300 bps benefit from reducing earn-out liability on an acquisition that did not perform to its business case largely compensated for the operational headwinds, keeping EBIT margin flat QoQ at 14.45%.
- Full-year margin declined: FY24 EBIT margin fell to 14.4% from 14.9% in FY23, attributed to investments in sales and marketing capacity and next-gen technology assets including AI.
- Contractor costs rose as a deliberate lever: Contractor cost reached 14.1% of revenues as Persistent used contractors for initial onsite ramp-up on large vendor consolidation deals; management views this as a future margin lever when transitions complete and offshore shift happens.
- Line of sight to 14.5% normalized: Excluding one-time items, management sees a clear path to 14.5% EBIT margins in normal operations through sub-contractor cost reduction, utilization improvement, and normalization of transition and travel costs.
Kalra: "Improving margin is an easier task versus getting higher growth. So, for this year we'll focus on growth and at any point in time if we can improve the margins, rest assured we'll do our best to improve the margins."
Top Customer & Client Concentration
- Planned decline, not a surprise: The top 1 customer declined $3.2 mn QoQ, continuing a planned partial ramp-down of a large five-year deal announced in FY23. Productivity improvements are built into the contract year-on-year, with no re-negotiation or contract opening.
- Concentration rose alongside growth: Top 10 customers reached 40% contribution, partly driven by growth in a couple of large relationships across Healthcare Life Sciences and BFSI.
- Hi-tech segment masked by the top client: Hi-Tech & Emerging declined 0.9% QoQ overall, but excluding the top 1 customer, the segment grew 1.6% QoQ. The segment faces headwinds as enterprise customers, which dominate Persistent's hi-tech exposure, are under pressure in their downstream purchasing.
- No rescoping, but COLA pushback emerging: Management sees no major contract rescoping across the portfolio. However, very large customers are increasingly trying not to give COLA when it is due, which management flagged as a trend worth watching.
Kalra: "So, some of the ramp downs are planned ramp downs. So, when we do larger deals, there are productivity things built year-on-year and so these are not any surprises. So, if there was any surprises that would have been told very clearly."
Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| Healthcare & Life Sciences | ▲ Strong growth | Grew 15% QoQ on a large win plus sustained momentum; team built over years; expected to lead FY25 growth. |
| BFSI | ▲ Incremental improvement | Grew 2% QoQ; new logo ramp-ups should accelerate; Persistent positioned as a challenger where clients are fatigued with larger incumbents. |
| Hi-Tech & Emerging | ▼ Declined (headline) | Declined 0.9% QoQ due to top customer ramp-down; ex-top-1 grew 1.6%. Enterprise software headwinds expected for next few quarters. |
- BFSI challenger positioning: Persistent is gaining from customers dissatisfied with larger incumbents, opening fairly large logos where ramp-ups are underway and should accelerate with time.
- Europe hopes to turn the corner: Over the next several quarters, management expects to turn the corner on Europe growth, supported by a new Europe Financial Services leader and pipeline build.
- Managed services as PE carveout specialist: Persistent has built a niche as a private equity carveout specialist, winning significant deals over the last three years where PE carveouts create greenfield IT and multi-year managed services engagements.
AI, GenAI & SASVA Platform
- SASVA launched as an accelerator, not a product: The digital engineering-powered enterprise AI platform addresses repository-level coding and planning, using hybrid language models including fine-tuned small language models on low-cost infrastructure to address high GenAI costs. Clients have asked to license it, but Persistent intends to use it to capture more value in services, not as a standalone product.
- Outcome-linked deal using SASVA: A leading enterprise software company signed an outcome-linked deal covering sustaining engineering and feature enhancements on a code repository of over 0.55 crore lines of code, with metrics tied to technical debt reduction, shortened release cycles, and revenue acceleration.
- GenAI Hub for multi-model adoption: Launched a platform for enterprise GenAI adoption across LLMs and clouds with no provider lock-in, integrated with existing assets and pre-built accelerators.
- Two GenAI enterprise deals closed: A three-year deal to build a GenAI-based straight-through processing platform for a listed U.S. insurance distribution corporation, and a GenAI-based recommendation engine for a large analytical instruments corporation using Azure OpenAI and GPT-4.
- IBM partnership expanded: Signed the IBM Services Business Partner Agreement to jointly work on deals and co-create assets on watsonx.data and AI platform.
- Life Sciences AI use cases broad: Persistent is involved across pharma, scientific instruments, medical devices, and payer/provider segments with AI/ML and GenAI use cases.
Kalra: "Our attempt here is not to use this as a product, but use this as an accelerator, as an IT that we will use so that we can retain the value and capture more value in services as we go around rather than just using it as another part of our Accelerite business or payments."
People, Capacity & Investments
- Headcount build tilted lateral: Most headcount increase in Q4 came from lateral hires; onsite hiring was linked to revenue ramp-up, while offshore hiring served both current ramp-up and capacity buildup for future transitions.
- Freshers entering billable pool: Freshers from Q2 entered the billable pool in Q4, contributing to the utilization dip from 81.5% to 80% but with no direct cost impact; this capacity is expected to become a margin lever in subsequent quarters.
- Attrition in a comfortable band: Attrition has declined over the last few quarters and is now in line with the broader industry trend.
- Senior leadership strengthened: Key hires include a Chief Strategy and Growth Officer, a Europe Financial Services leader, and a Chief Operating Officer, alongside other senior additions to build muscle for scaling toward the $2 bn aspiration.
- Investment intensity stays high: Sales and marketing capacity and GenAI capability-building remain at heightened levels; management is explicit that the first job is industry-leading growth, and margin expansion will follow when demand improves and over-investment can normalize.
Kalra: "Whether it is a bad economy or a good economy, we are preparing ourselves to go to $2 bn and much beyond."
Capital Allocation & Financial Position
- Free cash flow surged: Free cash flow reached ₹732.5 crore vs ₹92.5 crore last year, driven by the absence of acquisitions during the year.
- PAT crossed ₹1,000 crores for the first time.
- Final dividend of ₹10 per share recommended by the board, subject to shareholder approval.
- ETR to stay at 24.5%: Q4 ETR of 20.3% benefited from tax credit on ESOP perquisite income reported by U.S. employees; full-year ETR was 24.5%, and management expects the same range for FY25.
- M&A focus defined: Targeting tuck-in acquisitions at the cusp of Healthcare Life Sciences or BFSI and Data/AI; within Healthcare, looking at the payer-provider ecosystem; geographically targeting Western Europe for business and Eastern Europe for delivery. Not pursuing acquisitions for revenue aggregation.
- Carbon neutrality by mid-FY25: Aspiration to achieve carbon neutrality for Scope 1 and Scope 2 emissions and 100% renewable energy sourcing by the middle of FY25.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Medium-term margin expansion | Improve margins by 200-300 bps from current levels | Next 2-3 years |
| FY25 growth trajectory | Maintain top-quartile, industry-leading growth while holding margins at current-year levels | FY25 |
| Carbon neutrality | Achieve carbon neutrality for Scope 1 & 2 emissions, 100% renewable energy sourcing | Mid-FY25 |
| ETR range | Remain at 24.5% | FY25 |
| Healthcare-led growth | Healthcare to lead FY25 growth, followed by BFSI, then Tech | FY25 |
| Hi-tech segment pressure | Enterprise software headwinds to persist | Next few quarters |
| Europe turnaround | Turn the corner on Europe growth | Next several quarters |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue (USD) | $310.9 million, +3.4% QoQ and +13.2% YoY |
| Revenue (INR) | ₹2,590.5 crore, +3.7% QoQ and +14.9% YoY |
| Constant currency revenue growth | 3.4% QoQ |
| EBIT margin | 14.45%, flat QoQ; one-time transition costs and lower utilization offset by earn-out liability reduction |
| Profit after tax | ₹315.32 crore, 12.2% of revenue |
| Earnings per share (FY24) | ₹144.87, +17.1% YoY on like-to-like ₹10 face value |
| Total contract value (TCV) | $447.7 million, with new bookings TCV of $302 million |
| Annual contract value (ACV) from new bookings | $184.5 million |
| Healthcare & Life Sciences revenue growth | 15% QoQ |
| BFSI revenue growth | 2% QoQ |
| Hi-Tech & Emerging vertical revenue growth | -0.9% QoQ, +1.6% QoQ excluding top 1 customer |
| Top 10 client revenue contribution | 40% of revenue, first time since Q1 FY23 |
| Total headcount | 23,850, net increase of 514 QoQ |
| Blended utilization | 80%, down from 81.5% in Q3 |
| Trailing 12-month attrition | 11.5%, improved from 11.9% in Q3 |
| Dividend per share (final, recommended) | ₹10 on face value of ₹5 per share; total FY24 dividend ₹52 per share |
| Days sales outstanding | 63 days, improved from 66 days in Q3 |
| Operating cash flow to EBITDA | 0.76 for Q4, 0.73 for full year FY24 |